Antifungal Drugs Market – By Drug Class (Azoles, Echinocandins), Indication (Candidiasis, Aspergillosis), Infection Type (Systemic, Superficial), Route of Administration, Medication, Type, Distribution Channel & Forecast 2024 – 2032

Antifungal Drugs Market Size

Antifungal Drugs Market was valued at USD 15.5 billion in 2023 and is anticipated to witness growth at a CAGR of 3.7% to reach USD 21.2 billion by 2032. The increasing prevalence of fungal infections fueled by factors such as a growing geriatric population, rising prevalence of chronic diseases, and a higher number of immunocompromised patients is majorly contributing to the market growth.
 

For instance, as per the National Institute of Health (NIH), fungal infections are a significant health concern globally, with over 150 million severe cases occurring annually, leading to approximately 1.7 million deaths per year. Thus, this substantial number of patients with fungal infections drives the adoption of the antifungal drugs. Additionally, advancements in diagnostic techniques leading to improved identification of fungal infections are driving the demand for antifungal drugs. Furthermore, the development of novel antifungal therapies with improved efficacy and safety profiles, along with the expanding applications of antifungal drugs in prophylaxis, are expected to fuel market growth.
 

Antifungal drugs are a class of medications specifically designed to treat fungal infections caused by different types of fungi. Antifungal drugs are used to treat a wide range of fungal infections, including superficial infections like athlete's foot, ringworm treatment, and vaginal yeast infections, as well as systemic infections like invasive candidiasis and aspergillosis.
 

Antifungal Drugs Market Trends

• The growing prevalence of fungal infections including both common superficial infections and severe systemic infections, drives demand for antifungal medications to manage and treat these conditions.
   
• Factors such as the rising incidence of immunocompromised populations due to diseases like HIV/AIDS, the widespread use of immunosuppressive therapies, and the growing number of invasive medical procedures contribute to the higher susceptibility to fungal infections. For instance, the incidence of fungal infections in people living with HIV/AIDS, particularly opportunistic fungal infections, remains a significant concern. Cryptococcal meningitis, caused by C. neoformans, is a major issue for individuals with HIV/AIDS, with an estimated 152,000 cases occurring worldwide each year.
   
• To cater to this increasing demand for antifungal drugs, pharmaceutical companies are investing in research and development efforts to introduce innovative antifungal drugs, thereby driving market growth.
   
• In addition to this, increased awareness among healthcare professionals about the importance of fungal infection diagnosis and management leads to higher rates of diagnosis and prescription of antifungal medications, further boosting the overall market growth.
   

Antifungal Drugs Market Analysis

Based on drug class, the market is classified into azoles, echinocandins, polyenes, allylamines, and other drug classes. The azoles segment dominated the market with 48.2% of revenue share in 2023.
 

• Azoles exhibit a broad spectrum of activity against a wide range of fungal pathogens, including Candida species, Aspergillus species, and dermatophytes. Their versatility in treating both superficial and systemic fungal infections makes them a preferred choice for healthcare providers.
   
• Additionally, widespread availability of azoles in various formulations, including oral tablets, capsules, creams, and solutions increases the adoption of this drugs, thereby boosting the market share of this segment.
   

Based on indication, the market is segmented into candidiasis, aspergillosis, dermatophytosis, mucormycosis, and other indications. The candidiasis segment accounted for USD 5.5 billion revenue in 2023.
 

• Candidiasis, caused by Candida species, is one of the most common fungal infections globally. For instance, according to Centers of Disease Control and Prevention (CDC), in 2021, candidiasis caused around 1,769 deaths in U.S.
   
• Additionally, increasing prevalence and severity of this diseases has increased the awareness about the diagnosis and treatment of the diseases. Hence, the demand of antifungal drugs for treating candidiasis has increased, reinforcing the dominance of this segment in the market.
   
• Furthermore, the treatment of candidiasis benefits from the availability of a wide range of antifungal drug classes such as azoles (e.g., fluconazole, voriconazole), echinocandins (e.g., caspofungin, micafungin), and polyenes, thereby contributing to the growth of this segment.
   

Based on infection type, the antifungal drugs industry is divided into systemic antifungal infections and superficial antifungal infections. The systemic antifungal infections segment held majority of market share and is predicted to grow at CAGR of 3.1% over the analysis period.
 

• Systemic fungal infections are associated with substantial morbidity and mortality. The high incidence of these life-threatening infections drives demand for effective antifungal medications to treat systemic fungal infections.
   
• Further, the availability of targeted antifungal therapies, such as echinocandins and azoles with enhanced activity against systemic fungal pathogens, has revolutionized the management of systemic fungal infections. These factors collectively aid in propelling the growth of this segment.
   

Based on route of administration, the antifungal drugs market is categorized into oral, topical, and injectable. The oral segment held high market share in 2023 and is anticipated to reach USD 7.9 billion by the end of forecast timeframe.
 

• Oral antifungal medications offer convenience and ease of administration, allowing patients to self-administer treatment at home without the need for healthcare professional assistance. This convenience factor leads to higher patient adherence and satisfaction, contributing to the widespread preference for oral formulations.
   
• Moreover, oral antifungal drugs are often more cost-effective than intravenous formulations, making them preferred options for both patients and healthcare providers. Thus, the affordability and accessibility of oral antifungal drugs drives their dominance in the market.
   

Based on medication, the market is segmented into prescription and OTC. The prescription segment dominated the market and is expected to showcase lucrative growth at 3%.
 

• Many antifungal medications require a prescription from a qualified healthcare professional due to their potency, potential side effects, and the need for proper diagnosis and management of fungal infections.
   
• Additionally, healthcare providers play a crucial role in assessing patients' medical history, determining the type and severity of the fungal infection, and prescribing the most appropriate antifungal therapy based on individual patient factors.
   
• This reliance on prescription-based medications ensures that patients receive optimal treatment tailored to their specific needs, contributing to the dominance of the prescription segment in the market.
   

Based on type the antifungal drugs market is categorized into branded and generic. Branded segment held notable market share of 70.3% in 2023.
 

• Branded antifungal medications often benefit from extensive research and development investments made by pharmaceutical companies to discover and develop innovative therapies. These branded drugs typically undergo rigorous clinical trials to demonstrate their safety, efficacy, and superiority over existing treatments, leading to their approval by regulatory authorities.
   
• This strong scientific evidence supporting branded antifungal drugs enhances their credibility among healthcare providers, leading to increased prescription of branded antifungal drugs, which further contributes to the growth of this segment.
   

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market and was valued at USD 7 billion in 2023.
 

• The dominance of hospital pharmacies in the global antifungal drugs industry is underscored by their pivotal role in managing severe fungal infections among hospitalized patients.
   
• With the prevalence of conditions like candidemia and invasive aspergillosis higher among those admitted, hospital pharmacies serve as essential hubs for dispensing and managing a diverse range of antifungal medications.
   
• Furthermore, streamlined procurement and distribution processes within hospital pharmacies facilitate timely access to oral, topical, and intravenous formulations, supporting efficient medication management workflows and growth of the segment
   

North America dominated the global antifungal drugs market size in 2023 with a revenue of USD 6.4 billion and is anticipated to grow at a CAGR of 3.3% over the forecast period.
 

• High regional growth can be attributed to the advanced healthcare infrastructure and sophisticated medical facilities, which facilitate early diagnosis, treatment, and management of fungal infections.
   
• This robust healthcare ecosystem ensures widespread access to antifungal medications and fosters collaboration between healthcare providers, pharmaceutical companies, and regulatory authorities, positioning North America at the forefront of antifungal drug development and utilization.
   
• Moreover, the high prevalence of fungal infections in North America, particularly among vulnerable populations such as immunocompromised individuals, critically ill patients, and the elderly, contributes to the substantial demand for antifungal drugs.
   

Antifungal Drugs Market Share

The antifungal drugs industry is characterized by intense competition among key players striving to gain a significant market share. Major pharmaceutical companies and generic drug manufacturers are actively involved in research, development, and commercialization of antifungal medications. Strategic collaborations, partnerships, mergers, and acquisitions are common strategies employed by key players to strengthen their market position and capitalize on emerging opportunities in the global market.
 

Antifungal Drugs Market Companies

Prominent players operating in the antifungal drugs industry include:

• Abbott Laboratories
• Astellas Pharma, Inc.
• Bayer AG
• Enzon Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Glenmark
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi
   

Antifungal Drugs Industry News:

• In December 2023, Astellas Pharma announced the U.S. FDA approval of CRESEMBA, an azole antifungal drug for treating invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. This FDA approval helped the company to diversify their product portfolio and boost their revenue.
   
• In January 2023, Sandoz signed agreement with Astella to acquire worldwide product rights for leading systemic antifungal agent Mycamine. This strategic move helped the company to expand product portfolio, increase market access, and revenue generation.
   

The antifungal drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Other drug classes

Market, By Indication

• Dermatophytosis
• Aspergillosis
• Candidiasis
• Mucormycosis
• Other indications

Market, By Infection Type

• Systemic antifungal infections
• Superficial antifungal infections

Market, By Route of Administration

• Oral
• Topical
• Injectable

Market, By Medication

• Prescription
• OTC

Market, By Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa